CDC HIV/Hepatitis/STD/TB Prevention News Update 08/12/2008อาจารย์น.พ. ธาดา ยิบอินซอยกรุณาส่งมาให้ค่ะ CDC HIV/Hepatitis/STD/TB Prevention News Update 08/12/2008 SOUTH AFRICA: TB Drug Interferes with Key AIDS Treatment: Study Agence France Presse (08.03.08) In a study presented ahead of the 17th International AIDS Conference in Mexico City, researchers led by Andrew Boulle of the University of Cape Town found the TB drug rifampicin reduces concentrations of an HIV/AIDS treatment widely used in Africa and other hard-hit regions. From 2001 to 2006, a group of patients in South Africa who were initiating antiretroviral treatment was studied. Of these, 2,035 were started on efavirenz, of whom 1,074 were co-infected with TB. Another 1,935 were placed on nevirapine, of whom 209 also had TB. In the nevirapine group, 16.3 percent of patients with TB were almost twice as likely to have elevated levels of HIV in their blood at six-month follow-up, compared to just 8.3 percent among those without TB. In addition, these patients were twice as likely to develop treatment failure faster than patients without TB infection. However, 80 percent of TB patients using nevirapine succeeded in suppressing the virus at an 18-month follow-up. HIV/TB co-infection can result in a rapid decline in patients health, especially if the TB strain is resistant to frontline antibiotics. The death rate for co-infected patients is five times that of patients with TB alone. According to the researchers, it is not clear why rifampicin impacted nevirapine therapy. One possible explanation could be shared toxicity. Another could be drug interaction caused by rifampicin when the patient began antiretroviral treatment. The study, Outcomes of Nevirapine- and Efavirenz-Based Antiretroviral Therapy When Coadministered with Rifampicin-Based Antitubercular Therapy, was published in the Journal of the American Medical Association (2008;300(5):530-539). Posted by : chpantip , E-mail : (chpantip@medicine.psu.ac.th) , Date : 2008-08-13 , Time : 08:30:49 , From IP : 172.29.3.68 |
